公开(公告)号：US20240353404A1

公开(公告)日：2024-10-24

申请号：US18634194

申请日：2024-04-12

Applicant: Mayo Foundation for Medical Education and Research

Inventor： Sanjeev Sethi ,  Fernando C. Fervenza ,  Benjamin J. Madden

IPC: G01N33/564 ,  A61K38/13 ,  A61K39/00 ,  A61P13/12 ,  C07K16/28

CPC classification number: G01N33/564 ,  A61K38/13 ,  A61P13/12 ,  C07K16/2887 ,  A61K2039/505 ,  G01N2333/96411 ,  G01N2800/347

Abstract: This document relates to methods and materials involved in identifying and/or treating mammals having membranous nephropathy (e.g., membranous nephropathy with an elevated level of a proprotein convertase subtilisin/kexin type 6 (PCSK6) polypeptide in kidney tissue such as the glomerular basement membrane (GBM)). For example, methods and materials for administering one or more immunosuppressive agents to treat a mammal (e.g., a human) identified as having membranous nephropathy are provided.

公开(公告)号：US20230348610A1

公开(公告)日：2023-11-02

申请号：US17758361

申请日：2021-03-05

Applicant: Mayo Foundation for Medical Education and Research

Inventor： Sanjeev Sethi ,  Fernando C. Fervenza ,  Benjamin J. Madden ,  M. Cristine Charlesworth

IPC: C07K16/28 ,  A61P13/12 ,  G01N33/68

CPC classification number: C07K16/2887 ,  A61P13/12 ,  G01N33/686 ,  C07K2317/24 ,  C07K2317/732 ,  C07K2317/734 ,  G01N2800/24

Abstract: This document relates to methods and materials involved in identifying and/or treating mammals having membranous nephropathy (e.g., membranous nephropathy with an elevated level of a Semaphorin 3B polypeptide in the glomerular basement membrane (GBM)). For example, methods and materials for administering one or more immunosuppressive agents (e.g., corticosteroids, cyclosporine, or a B-cell reduction or depletion agent such as Rituximab) to treat a mammal (e.g., a human) having membranous nephropathy are provided.

公开(公告)号：US20230400465A1

公开(公告)日：2023-12-14

申请号：US18033903

申请日：2021-10-29

Applicant: Mayo Foundation for Medical Education and Research

Inventor： Fernando C. Fervenza ,  Sanjeev Sethi

IPC: G01N33/573 ,  G01N33/68

CPC classification number: G01N33/573 ,  G01N33/6893 ,  G01N33/6848 ,  G01N2800/347 ,  G01N2001/2886

Abstract: This document provides methods and materials involved in identifying and treating mammals (e.g., humans) having membranous nephropathy. For example, methods and materials for determining the likelihood that a mammal (e.g., a human) having membranous nephropathy (e.g., lupus membranous nephropathy) will progress to end stage kidney disease are provided. Methods and materials for treating membranous nephropathy likely to develop end stage kidney disease also are provided.

公开(公告)号：US20210270832A1

公开(公告)日：2021-09-02

申请号：US17254086

申请日：2019-08-15

Applicant: Mayo Foundation for Medical Education and Research

Inventor： M. Cristine Charlesworth ,  Sanjeev Sethi ,  Fernando C. Fervenza ,  Benjamin J. Madden

IPC: G01N33/564

Abstract: This document provides methods and materials involved in identifying and treating mammals (e.g., humans) having membranous nephropathy. For example, methods and materials for detecting the presence of autoantibodies specific for an EXT1 and/or EXT2 polypeptide as well as methods and materials for detecting the presence of kidney tissue having an elevated level of an EXT1 and/or EXT2 polypeptide are provided. In addition, methods and materials for treating membranous nephropathy by administering an immunosuppressant are provided.

公开(公告)号：US12203933B2

公开(公告)日：2025-01-21

申请号：US17254086

申请日：2019-08-15

Applicant: Mayo Foundation for Medical Education and Research

Inventor： M. Cristine Charlesworth ,  Sanjeev Sethi ,  Fernando C. Fervenza ,  Benjamin J. Madden

IPC: G01N33/564

Abstract: This document provides methods and materials involved in identifying and treating mammals (e.g., humans) having membranous nephropathy. For example, methods and materials for detecting the presence of autoantibodies specific for an EXT1 and/or EXT2 polypeptide as well as methods and materials for detecting the presence of kidney tissue having an elevated level of an EXT1 and/or EXT2 polypeptide are provided. In addition, methods and materials for treating membranous nephropathy by administering an immunosuppressant are provided.

公开(公告)号：US20240245712A1

公开(公告)日：2024-07-25

申请号：US18413949

申请日：2024-01-16

Applicant: Mayo Foundation for Medical Education and Research

Inventor： Sanjeev Sethi ,  Fernando C. Fervenza ,  Benjamin J. Madden

IPC: A61K31/65 ,  A61K31/43 ,  A61P13/12 ,  G01N33/564

CPC classification number: A61K31/65 ,  A61K31/43 ,  A61P13/12 ,  G01N33/564 ,  G01N2800/347

Abstract: This document relates to methods and materials involved in identifying and/or treating mammals having membranous nephropathy (e.g., membranous nephropathy with an elevated level of a neuron-derived neurotrophic factor (NDNF) polypeptide in the glomerular basement membrane (GBM)). For example, methods and materials for administering one or more antimicrobial agents to treat a mammal (e.g., a human) having membranous nephropathy are provided.

公开(公告)号：US20230314425A1

公开(公告)日：2023-10-05

申请号：US18021641

申请日：2021-09-01

Applicant: Mayo Foundation for Medical Education and Research

Inventor： Sanjeev Sethi ,  Fernando C. Fervenza ,  Benjamin J. Madden ,  M. Cristine Charlesworth

IPC: G01N33/564 ,  A61K45/06

CPC classification number: G01N33/564 ,  A61K45/06 ,  G01N2800/347

Abstract: This document relates to methods and materials involved in identifying and/or treating mammals having membranous nephropathy (e.g., membranous nephropathy with an elevated level of a PCDH7 polypeptide in the glomerular basement membrane (GBM)). For example, methods and materials for administering one or more immunosuppressive agents (e.g., corticosteroids, cyclosporine, or a B-cell reduction or depletion agent such as Rituximab) to treat a mammal (e.g., a human) having membranous nephropathy are provided.

公开(公告)号：US20220389108A1

公开(公告)日：2022-12-08

申请号：US17642773

申请日：2020-09-18

Applicant: Mayo Foundation for Medical Education and Research

Inventor： Sanjeev Sethi ,  Fernando C. Fervenza ,  Benjamin J. Madden ,  M. Cristine Charlesworth

IPC: C07K16/28 ,  G01N33/564 ,  A61K38/13 ,  A61K31/436 ,  A61K31/196 ,  A61P37/06

Abstract: This document relates to methods and materials involved in identifying and/or treating mammals having membranous nephropathy (e.g., membranous nephropathy with an elevated level of a neural epidermal growth factor (EGF)-like 1 (NELL-1) polypeptide in the glomerular basement membrane (GBM)). For example, methods and materials for administering one or more immunosuppressive agents (e.g., corticosteroids, cyclosporine, or a B-cell reduction or depletion agent such as Rituximab) to treat a mammal (e.g., a human) having membranous nephropathy are provided.